What question did this study set out to answer?

The study aims to assess the safety and immunogenicity of mRNA vaccines targeting H10N8 and H7N9 influenza viruses in healthy adults.

May 1, 2019VaccineOpen Access

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates safety and immune response of mRNA vaccines in healthy adults, suggesting strong efficacy against avian influenza viruses.

The study aims to assess the safety and immunogenicity of mRNA vaccines targeting H10N8 and H7N9 influenza viruses in healthy adults.
Two randomized, double-blind, placebo-controlled phase 1 trials were conducted in Germany and the USA.
Healthy adults received mRNA vaccines or placebo in a 2-dose series, with diverse dose levels evaluated.
Safety and immunogenicity were measured through various assays including hemagglutination inhibition and microneutralization assays.
For H10N8, the 100-µg IM dose induced HAI titers ≥ 1:40 in 100% of participants with MN titers ≥ 1:20 in 87%.
For H7N9, IM doses showed HAI titers ≥ 1:40 in 36.0% (10 µg), 96.3% (25 µg), and 89.7% (50 µg).
Both vaccines demonstrated good safety profiles with no serious adverse events reported.

Feldman et al. (2019) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates safety and immune response of mRNA vaccines in healthy adults, suggesting strong efficacy against avian influenza viruses.